NAVB

Navidea Biopharmaceuticals Inc.
NAVB
Market cap $4.39M

Delisted

NAVB was delisted on the 25th of April, 2019.

Back to rankings

Healthcare Diagnostics & Research

Financial journalist opinion

Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split

COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the extension of its authority to implement a reverse stock split of its common stock at a ratio of up to 1-for-50,000 shares. The Company originally received shareholder approval to amend its Certificate of Incorporation to authorize a reverse stock split at.

Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split

Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets

COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”) today announced that its Board of Directors has elected to extend the Company's Section 382 Rights Agreement (the “Section 382 Rights Plan”). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027. The Section 382 Rights Plan is designed to safeguard Navidea's ability to utilize its net operating loss carryforwards (“NOLs”) and other ta.

Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets

Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024

COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the Company's pivotal NAV3-33 clinical trial titled “Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (R.

Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024

Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024

COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024. The purpose of the special meeting is to consider and vote upon (i) an amendment to the Company's certificate of incorporation to allow stockholders to act by written consent, and (ii.

Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024

Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations

COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations.

Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release.

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release

See News Rankings

Charts implemented using Lightweight Charts™